A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Brekman, Angelika ^a   Singh, Kathryn E ^a   Polotskaia, Alla ^a   Kundu, Nandini ^a   Bargonetti, Jill ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL NUCLEUS; CHROMATIN; DRUG EFFECT; FEMALE; GENE SILENCING; GENETICS; METABOLISM; PROTEIN TRANSPORT; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN; ESTRADIOL; FEMALE; GENE SILENCING; HUMANS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860389938     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2804     Document Type: Article

References (60)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
2. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13:293-325. 10.1677/erc.1.01172, 16728565.
3. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999, 80:1968-1973. 10.1038/sj.bjc.6690628, 2363143, 10471047.
4. Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997, 13:27-33. 10.1016/S0168-9525(96)10043-3, 9009845.
5. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998, 26:3453-3459. 10.1093/nar/26.15.3453, 147746, 9671804.
6. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res 2006, 66:5104-5110. 10.1158/0008-5472.CAN-06-0180, 16707433.
7. Sheikh MS, Shao Z, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993, 53:3226-3228.
8. Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 2003, 63:2616-2623.
9. Martin M. Molecular biology of breast cancer. Clin Transl Oncol 2006, 8:7-14. 10.1007/s12094-006-0089-6, 16632434.
10. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004, 50:3-22. 10.1016/j.critrevonc.2003.09.003, 15094156.
11. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 2005, 25:7917-7925. 10.1128/MCB.25.17.7917-7925.2005, 1190308, 16107734.
12. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000, 20:2890-2901. 10.1128/MCB.20.8.2890-2901.2000, 85519, 10733592.
13. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006, 281:9837-9840. 10.1074/jbc.C600001200, 16469747.
14. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007, 67:7746-7755. 10.1158/0008-5472.CAN-06-3724, 17699779.
15. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, Stolovitzky G, Levine AJ. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007, 67:2757-2765. 10.1158/0008-5472.CAN-06-2656, 17363597.
16. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, Press MF. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001, 61:3212-3219.
17. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 2006, 19:69-74. 10.1038/modpathol.3800484, 16258514.
18. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 2003, 23:5867-5881. 10.1128/MCB.23.16.5867-5881.2003, 166332, 12897156.
19. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Hayashi S. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 2001, 281:259-265. 10.1006/bbrc.2001.4339, 11178989.
20. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
21. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin associated and transcriptionally inactive p53-MDM2 complex occurs in MDM2 SNP 309 homozygous cells. J Biol Chem 2005, 280:26776-26787. 10.1074/jbc.M505203200, 15908423.
22. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993, 8:3411-3416.
23. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'ev A. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 2002, 64:865-871. 10.1016/S0006-2952(02)01149-8, 12213580.
24. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003, 1:1001-1008.
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992, 69:1237-1245. 10.1016/0092-8674(92)90644-R, 1535557.
26. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860. 10.1038/362857a0, 8479525.
27. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7:1126-1132. 10.1101/gad.7.7a.1126, 8319905.
28. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997, 11:1974-1986. 10.1101/gad.11.15.1974, 316412, 9271120.
29. Minsky N, Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 2004, 16:631-639. 10.1016/j.molcel.2004.10.016, 15546622.
30. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. Embo J 2003, 22:6365-6377. 10.1093/emboj/cdg600, 291841, 14633995.
31. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008, 7:979-987. 10.1038/nrd2656, 19043449.
32. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283. 10.1038/nrm2147, 17380161.
33. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309:1732-1735. 10.1126/science.1114297, 16151013.
34. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 25:5815-5824. 10.1200/JCO.2007.11.3886, 17893378.
35. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002, 99:95-100. 10.1073/pnas.012283399, 117520, 11756653.
36. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 2000, 97:11250-11255. 10.1073/pnas.210171597, 17186, 11016968.
37. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett 2006, 580:5647-5652. 10.1016/j.febslet.2006.09.013, 1876739, 16996503.
38. Shanmugam M, Krett NL, Maizels ET, Cutler RE, Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST, Hunzicker-Dunn M. Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line. Mol Cell Endocrinol 1999, 148:109-118. 10.1016/S0303-7207(98)00229-9, 10221776.
39. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992, 89:7262-7266. 10.1073/pnas.89.15.7262, 49686, 1353891.
40. Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, Armetta I, Abbondanza C, Puca GA. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000, 60:2594-2597.
41. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002, 70:537-546. 10.1046/j.1432-0436.2002.700907.x, 2933198, 12492495.
42. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96. 10.1016/j.molonc.2007.02.004, 2391005, 18516279.
43. Gudas JM, Oka M, Diella F, Trepel J, Cowan KH. Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. Cell Growth Differ 1994, 5:295-304.
44. Hori M, Shimazaki J, Inagawa S, Itabashi M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 2002, 71:77-83. 10.1023/A:1013350419426, 11859876.
45. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008, 7:2427-2433. 2926973, 18677110.
46. Espinosa JM. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 2008, 27:4013-4023. 10.1038/onc.2008.37, 2914794, 18278067.
47. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006, 13:1109-1120. 10.1677/erc.1.01120, 17158757.
48. Mobley JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004, 25:3-9. 10.1093/carcin/bgg175, 14514655.
49. Chen Y, Liu X, Pisha E, Constantinou AI, Hua Y, Shen L, van Breemen RB, Elguindi EC, Blond SY, Zhang F, Bolton JL. A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 2000, 13:342-350. 10.1021/tx990186j, 10813650.
50. Yared E, McMillan TJ, Martin FL. Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis 2002, 17:345-352. 10.1093/mutage/17.4.345, 12110632.
51. Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, Carmouche RP, Ibberson D, Barath P, Demay F, Reid G, Benes V, Jeltsch A, Gannon F, Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452:45-50. 10.1038/nature06544, 18322525.
52. Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, Benes V, Gannon F, Reid G. Transient cyclical methylation of promoter DNA. Nature 2008, 452:112-115. 10.1038/nature06640, 18322535.
53. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004, 91:178-185. 10.1038/sj.bjc.6601902, 2364738, 15188005.
54. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002, 277:30838-30843. 10.1074/jbc.M204078200, 12068014.
55. Jin Y, Zeng SX, Lee H, Lu H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J Biol Chem 2004, 279:20035-20043. 10.1074/jbc.M309916200, 14769800.
56. Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE, Cariati M, Brindle K, Aparicio S, Caldas C. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004, 101:7386-7391. 10.1073/pnas.0401002101, 409928, 15123817.
57. Sun SH, Zheng M, Ding K, Wang S, Sun Y. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther 2008, 7.
58. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. Genes Dev 2003, 17:1115-1129. 10.1101/gad.1067003, 196049, 12695333.
59. Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, Telkoparan P, Gur-Dedeoglu B, Cingoz B, Bozkurt B, Tazebay UH, Yulug IG, Akcali KC, Ozturk M. The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity. PLoS One 2010, 5:e11288. 10.1371/journal.pone.0011288, 2891998, 20585577.
60. Sun P, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-beta1 resistance. Science 1998, 282:2270-2272. 10.1126/science.282.5397.2270, 9856953.